Geron Corporation ((GERN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants treated with imetelstat compared to BAT in patients who have not responded to JAK-inhibitor treatment, highlighting its potential significance in advancing treatment options for this patient group.
Intervention/Treatment: The study tests two treatments: the experimental drug imetelstat, administered intravenously at 9.4 mg/kg every 21 days, and the active comparator, Best Available Therapy (BAT), which includes various non-JAK-inhibitor treatments. The goal is to determine which treatment offers better survival outcomes for patients.
Study Design: This interventional study employs a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either imetelstat or BAT, with the possibility of crossover to imetelstat for those on BAT who meet specific criteria.
Study Timeline: The study began on April 12, 2021, with the latest update submitted on August 18, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
Market Implications: The ongoing study could significantly impact Geron Corporation’s stock performance and investor sentiment, especially if imetelstat demonstrates superior efficacy. Success in this trial could position Geron favorably against competitors in the myelofibrosis treatment market, potentially leading to increased market share and investor interest.
The study is ongoing, with further details available on the ClinicalTrials portal.